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1. Introduction 
Severe cutaneous adverse reactions (SCARs) are generally induced by drugs and encompass 
the conditions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), 
drug induced eosinophilia and systemic syndrome (DRESS) also known as drug induced 
hypersensitivity syndrome (DIHS), and acute generalized exanthematous pustulosis 
(AGEP).  These conditions, although rare, cause significant morbidity and are potentially 
fatal. It is therefore important for the treating physician to promptly recognize SCARs 
through the identification of their characteristic clinical features so that the offending drug is 
promptly withdrawn and supportive and adjunctive therapies are administered. SCARs are 
accompanied by particular abnormalities on routine laboratory investigations and skin 
biopsy that enables confirmation of the diagnosis and provision of useful prognostic 
information. Data bases have been established, predominantly in Europe, since the 1980s to 
characterize the epidemiology of SCARs including the identification of drugs with the 
highest relative risk and the latency between the commencement of drug intake and the 
onset of clinical manifestations. The pathogenesis of the various SCARs involves delayed T 
cell-mediated inflammation in a genetically predisposed individual and in the case of DIHS, 
may involve viral factors. The emerging field of the genetic susceptibility to SCARs has 
raised the important issue of pharmacogenetic screening as a method of predicting an 
individual’s risk of developing SCAR to a certain drug.   
2. Stevens-Johnson syndrome/toxic epidermal necrolysis 
2.1 History and nosology 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) were once considered 
as variants of erythema multiforme (EM), a condition first described by Ferdinand von 
Hebra in 1860 as a mild and relapsing eruption of target lesions affecting the acral regions. 
Mucosal involvement occurs in up to 70 % of cases of EM. In 1922, Albert Stevens and Frank 
Johnson described two cases of fever, stomatitis, purulent conjunctivitis, and a generalized 
eruption of purple papules in boys aged 7 and 8 years, respectively (Stevens and Johnson 
1922).  Both cases were distinguished from EM by the prolonged high fever, and the 
generalized distribution and heavy terminal crusting of the skin lesions. Bernard Thomas 
proposed two categories of EM in 1950: erythema multiforme minor, as described by von 
Hebra, and erythema multiforme major, a severe form that encompassed SJS (Thomas 1950). 
Alan Lyell termed the condition toxic epidermal necrolysis (TEN) after reporting four cases 
of an acute life threatening mucocutaneous disorder characterized by diffuse erythema 
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followed by extensive epidermal detachment manifesting as blistering and sloughing of the 
skin (Lyell 1956). Although SJS and TEN were initially considered distinct entities, it was 
later proposed that they form a continuum along the same disease process and differ mainly 
in the extent of involvement. It was also proposed that EM major and SJS are distinct 
conditions, with EM major characterised by acral target-like lesion typical of EM minor but 
with mucosal involvement. SJS was applied to cases of mucous membrane involvement and 
a more extensive eruption of atypical targetoid lesions, blisters or sloughing of the skin 
(Bastuji-Garin, Rzany et al. 1993). The distinction between EM and SJS are consistent with 
observations regarding differences in etiology, demography and histopathology and not just 
confined to variations in the severity of disease. Most cases of EM are related to infection 
especially those with recurrent disease, which is related to herpes simplex virus (HSV) 
infection (Ng, Sun et al. 2003) in contrast to SJS which usually is an idiosyncratic reaction to 
drugs (Mockenhaupt, Viboud et al. 2008). EM typically affects young adults in their 20s and 
30s although approximately 20% of cases involve children (Lam, Yang et al. 2004) whereas 
SJS/TEN occurs at any age (Mockenhaupt, Viboud et al. 2008). Histopathology in EM in 
contrast to SJS/TEN consists of a denser infiltrate of lymphocytes and less apoptosis of 
keratinocytes (Cote, Wechsler et al. 1995).  
In 1993, a classification scheme was proposed that is widely but not universally adopted that 
arbitrarily defines SJS and TEN according to the extent of epidermal detachment (Bastuji-
Garin, Rzany et al. 1993). In SJS, epidermal loss affects less than 10% of the total body 
surface area (TBSA) whereas TEN involves greater than 30% of the TBSA. Epidermal 
detachment between 10 and 30% of the TBSA is classified as SJS/TEN overlap.  
2.2 Epidemiology 
The epidemiology of SJS/TEN and other severe cutaneous adverse reactions (SCARs) has 
been more accurately determined in recent years due to registries that have been established 
mainly across Europe comprising cases that are reviewed by expert committees and based 
on predefined and validated criteria. A population-based registry was commenced in 
Germany in 1990 to collect all hospitalised cases of SJS, TEN and EM major. An international 
case-control study was conducted between 1989 and 1995 in France, Germany, Italy and 
Portugal (SCAR study) focusing on cases of SJS/TEN requiring hospitalisation. A European 
case-control surveillance study of SCARs (EuroSCAR study) was conducted between 1997 
and 2001 in Austria, France, Germany, Israel, Italy, and the Netherlands investigating both 
SJS/TEN and AGEP that resulted in admission to hospital. In 2003, the European registry on 
SCARs (RegiSCAR) was commenced collecting biological samples across the same countries 
that participated in the EuroSCAR study. This network, which is focused on SJS/TEN and 
AGEP, has spawned numerous studies on epidemiology, pharmacogenetics and 
histopathology and includes community cases that required hospitalisation as well as cases 
that developed during hospital admissions. These registries not only provide valuable 
information on the epidemiology of SCAR but they have enabled close scrutiny of the 
availability and prescription of high-risk drugs. For example, the SCAR study resulted in 
the withdrawal of chlormezanone from the market and restricted indications for 
cotrimoxazole and phenobarbitol (Roujeau 2005). 
The incidence of SJS/TEN is 1-2 cases/million inhabitants/year (Rzany, Mockenhaupt et al. 
1996). The EuroSCAR study published in 2008 comprised 379 cases that included 134 cases 
of SJS, 136 cases of SJS/TEN overlap, and 109 cases TEN spanning a geographical area 
encompassing over a 100 million inhabitants. The median age of cases was found to be 50 
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years (range 1-95 years), and a female preponderance (62% of cases) was noted 
(Mockenhaupt, Viboud et al. 2008). 
2.3 Etiology 
2.3.1 Drugs 
Drugs are nearly always the cause of SJS/TEN. Over 220 medications have been implicated but 
only relatively a few are responsible for the majority of cases.  The EuroSCAR study comprised 
379 cases of SJS/TEN and 1505 age-matched controls, who were patients admitted to hospital 
for other acute illnesses (Mockenhaupt, Viboud et al. 2008). Univariate relative risk (uRR) and 
multivariate relative risk (mRR) were calculated for each drug suspected of causing SJS/TEN. 
The drugs found to confer the highest risk were cotrimoxazole (uRR 102), other anti-bacterial 
sulphonamides (uRR 53), carbamazepine (mRR 72), nevirapine (uRR >22), allopurinol (mRR 
18), phenytoin (mRR 17), oxicam-NSAIDs (mRR 16), lamotrigine  (uRR >14), and sertraline 
(mRR 11). Drugs that were found to have a significant but lower risk included acetic acid-
NSAIDs, macrolides, quinolones, cephalosporins, tetracyclines and aminopenicillins. SJS/TEN 
typically occurs with drugs that are taken on a long-term basis. The median latency between the 
onset of medication use and the occurrence of SJS/TEN in the EuroSCAR study was found to be 
less than 4 weeks (range 1-8 weeks): carbamazepine 15 days, phenobarbitol 17 days, allopurinol 
20 days, phenytoin 24 days. Pantoprazole and tramadol were associated with high uRRs, 18 and 
20, respectively, but the frequent co-medication with highly suspected drugs and the timing of 
the onset of SJS/TEN were not suggestive of a true risk. Commonly used medications not 
associated with a risk of SJS/TEN included beta-blockers, ACE-inhibitors, calcium channel 
blockers, thiazide diuretics, furosemide, propionic acid-NSAIDs, sulphonylureas, and insulin. 
Interestingly, valproic acid was not shown to have a significant risk, which is contrast to 
previous observations (Roujeau, Kelly et al. 1995; Rzany, Correia et al. 1999). The most likely 
explanation is that valproic acid was frequently coadministered with high-risk drugs.   
A pooled analysis of the SCAR and EuroSCAR data was performed for children under 15 
years of age and showed that anti-bacterial sulphonamides, phenobarbitol, lamotrigine and 
carbamazepine were strongly associated with SJS/TEN in this paediatric population (Levi, 
Bastuji-Garin et al. 2009).  
2.3.2 Other causes 
Infection with Mycoplasma pneumoniae is a known cause of SJS especially in the paediatric 
population and a few cases of TEN have been reported to complicate infection with this 
agent (Lam, Yang et al. 2004). However, the EuroSCAR study, failed to show that infection 
was a risk factor either on its own although there is a suggestion that is may modestly 
increase the risk of SJS/TEN from medication. SJS/TEN has been reported in association 
with vaccinations (Ball, Ball et al. 2001) and exposure to industrial chemicals and fumigants 
(House, Jakubovic et al. 1992).  
2.4 Clinical  presentation 
SJS/TEN is characterized, as per the original descriptions, by fever, blistering skin eruption 
and severe mucositis. The skin lesions initially appear as atypical target –like or targetoid 
lesions, which are erythematous macules that contain a central purpuric blister (Fig. 1). 
Lesions are symmetrically distributed often starting on the face and thorax before spreading 
to other areas. The scalp is typically spared. Blisters result from epidermal detachment and 
they are easily breached resulting in dark red oozing erosions. Lesions exhibit Nikolsky’s 
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sign, which is epidermal separation induced by gentle lateral pressure applied to the skin 
surface. The skin then sloughs rapidly over several days as a result of separation of large 
sheets of the epidermis from the dermis. Fulminant cases of TEN have been reported where 
total loss of the epidermis occurs within 24 hours. New lesions may continue to erupt for up 
to 4 weeks. However, the growth of a new epithelium occurs after several days and 
individual lesions are completely re-epithelialized after a mean of 3 weeks. Cicatrization of 
the mucous membranes may take longer to complete.  
 
 
Fig. 1. Atypical target-like or targetoid lesions in a patient with SJS characterized by an 
erythematous macule with a central blister. 
At least two mucosal surfaces are involved in 90% of cases of SJS/TEN (Letko, Papaliodis et al. 
2005). Oropharyngeal involvement causes severe pain and odynophagia as a result of erosion 
and crusting (Fig. 2). Ocular regions may show a purulent conjunctivitis, pseudomembrane 
formation and corneal ulceration as a result of sloughing of conjunctival and corneal epithelia 
(Fig. 3). Urethritis may result in dysuria and even urinary retention. Sloughing of the tracheal 
and bronchial epithelium occurs in up to 30% of cases and may result in hypoxia, bronchial 
hypersecretion, pulmonary edema and bronchiolitis obliterans and the need for mechanical 
ventilation (Lebargy, Wolkenstein et al. 1997). The gastrointestinal tract can also be involved 
resulting in per rectal bleeding (Sugimoto, Mizutani et al. 1998).  
 
 
Fig. 2. Oral mucositis in a patient with SJS depicted as sloughing, necrosis and crusting of 
the inner labial surfaces. 
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Fig. 3. Purulent conjunctivitis in a patient with SJS accompanied by pseudomembrane 
formation, which results from sloughing of conjunctival and corneal surfaces. 
The mortality of SJS is generally below 10% whereas 30-50% of TEN patients die in the acute 
phase of the illness mostly as a result of skin failure. Infection and sepsis with multiorgan 
failure is the most common of death. The causative organisms are usually Staphylococcus 
aureus and Pseudomonas aeruginosa (Atiyeh, Dham et al. 2003). Fluid and electrolyte 
imbalances occur as a result of increased transepidermal water loss and impaired intake of 
nutrition due to odynophagia from stomatitis. Less common fatal complications include 
adult respiratory distress syndrome, pulmonary embolism and gastrointestinal 
haemorrhage (Wolkenstein and Revuz 2000; Abood, Nickoloff et al. 2008). Mortality is 
accurately predicted by the SCORTEN scale (Table 1) and should be computed within 24 
hours and 3 days following admission (Bastuji-Garin, Fouchard et al. 2000; Guegan, Bastuji-
Garin et al. 2006). 
 
Parameter Score 
Age >40 years 1 
Presence of malignancy 1 
Heart rate >120/min 1 
TBSA involved >10% 1 
Serum urea  > 10 mmol/L (28 mg/dL) 1 
Serum glucose >14 mmol/L (252 mg/dL) 1 
Serum bicarbonate <20 mmol/L (20 mEq/L) 1 
  
SCORTEN Mortality (%) 
0-1 3.2 
2 12.1 
3 35.3 
4 58.3 
≥5 90 
Table 1. SCORTEN 
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Chronic complications occur frequently following the acute phase of SJS/TEN. The most 
serious sequelae relate to the eye. The chronic ocular consequences are that of a cicatrization 
of the conjunctiva and symblepharon formation, severe dry eye, trichiasis, eyelid margin 
keratinization, and limbal stem cell deficiency, all of which combine to cause corneal 
ulceration and scarring and loss of vision. Patients may also experience chronic photophobia 
and eye pain. Skin sequelae include scarring, pigmentation abnormalities, and shedding of 
hair and nails. Vulvovaginal involvement can result in stenosis. Vulvar adenosis can occur 
in young women several years after resolution of the acute episode and can present with 
tender, erosive, haemorrhagic lesions. Phimosis can occur in men. Bronchopulmonary 
complications confer a poor prognosis and include chronic bronchitis, bronchiolitis 
obliterans, bronchiolitis obliterans with organizing pneumonia, and bronchiectasis. 
Oesophageal stricture and webbing has also been described and can result in dysphagia. 
2.5 Pathogenesis 
SJS/TEN results from the T- and NK-cell mediated extensive apoptosis of keratinocytes. The 
pharmaco-immune (p-i) concept, the mechanism by which the drug binds directly with the 
T cell receptor (TCR) causes activation of proapoptotic pathways. Granulysin is the major 
mediator of apoptosis in SJS/TEN. Apoptosis is also mediated through Fas-FasL interaction, 
and the release of granzyme and perforin.  
2.5.1 The pharmaco-immune (p-i) concept  
It is generally accepted that in SJS/TEN, the parent drug binds directly and non-covalently 
to the MHC and the TCR of primed effector and memory T cells (Pichler, Adam et al. 2010). 
Naïve T cells are not sufficiently stimulated by a p-i drug and additional signals are 
required (Pichler 2005). T cells may be primed by infection or autoimmune disease resulting 
in high cytokine levels such as IL-2 and IFN- resulting in increased expression of MHC and 
costimulatory molecules. This may provide an explanation for the increased incidence of 
drug hypersensitivity in inflammatory and infectious diseases. The drug may also bind to 
toll-like receptors resulting in the expression of costimulatory molecules by dendritic cells. 
For drugs such as cotrimoxazole, lamotrigine, and carbamazepine, the p-i concept may not 
be the sole mechanism involved; metabolites may also play a role through haptenization 
(Sanderson, Naisbitt et al. 2007).  
2.5.2 Granulysin 
A recent study by Chung et al using global gene expression profiling showed that 
granulysin RNA was the most significant cytotoxic molecule expressed in blister cells from 
patients with SJS/TEN. Granulysin protein concentrations were 2-4 times higher than 
perforin, granzyme B, and FasL and depleting granulysin reduced cytotoxicity (Chung, 
Hung et al. 2008). Granulysin is a cationic cytolytic protein produced by CTL, NK and NKT 
cells (Fig. 4A) (Gamen, Hanson et al. 1998). The 15-kDa-precursor form, found in blister 
fluid, induced skin necrosis when injected into mice and exhibited significant cytotoxicity in 
vitro. This contrasted with the minimal cytotoxicity induced by perforin, granzyme B, and 
FasL (Chung, Hung et al. 2008). Granulysin is also a proinflammatory molecule that causes 
an increase in the expression of chemokines (RANTES/CCL5, MCP-1, MCP-3, MIP-
1/CCL3) and cytokines (IL-1, IL-6, IFN-) resulting in the recruitment of T cells, 
monocytes and other inflammatory cells (Deng, Chen et al. 2005).  
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Fig. 4. SJS/TEN is primarily mediated by cytotoxic T cells. The drug binds to the CD8 T cell 
receptor and MHC via the pi concept resulting in their proliferation, activation and infiltration 
of these effector cytotoxic T cells (CTLs) into the skin (A). These CTLs may also bind drug that 
also binds to MHC class I molecules expressed on keratinocytes. Apoptosis of keratinocytes in 
SJS/TEN is caused primarily by the release of granulysin (A), but the ligation of Fas by FasL 
(B), and the degranulation of perforin and granzyme (C) may also play a role. 
A 
B
C 
www.intechopen.com
 Skin Biopsy – Perspectives 
 
124 
Fas-FasL, perforin/ granzyme and TNF pathways 
Viard et al, showed that the binding of FasL to Fas expressed on the surface of keratinocytes 
resulted in their apoptosis (Fig. 4B) (Viard, Wehrli et al. 1998). The cytoplasmic death domain 
of Fas undergoes conformational changes and trimerization upon recognition of FasL. This 
results in the recruitment of the Fas-associated death domain (FADD), which binds to 
procaspase 8 resulting in triggering of the caspase cascade and apoptosis. The source of the 
FasL is unclear. Viard et al showed that the FasL was is present on the surface of keratinocytes 
and in the serum of patients with TEN but not on the surface of keratinocytes or in the serum 
of patients with maculopapular exanthems and normal controls (Viard, Wehrli et al. 1998). A 
further study demonstrated that FasL was not constitutively expressed on the surface of 
keratinocytes but are transported to the cell membrane after damage to the keratinocyte 
(Viard-Leveugle, Bullani et al. 2003). Abe et al, however, found that the source of FasL was 
PBMCs and not keratinocytes (Abe, Shimizu et al. 2003).  
Nassif et al showed that mononuclear cells from blister fluid induce cytotoxicity via perforin 
and granzyme B (Nassif, Bensussan et al. 2002). This cytotoxicity was blocked by inhibiting 
perforin/granzyme but not by inhibiting Fas. Perforin and granzyme are proteins stored in 
the granules of CTLs. Upon recognition of a target cell, the CTL releases perforin, which 
create 16-nm channels in the target cell membrane. Granzyme B, a protease passes through 
these channels to activate the caspase cascade (Fig. 4C). The loss of T regulatory cell function 
in the acute stage of SJS/TEN may further contribute to the epidermal damage caused by 
effector T cells (Takahashi, Kano et al. 2009). 
Posadas et al, showed that both Fas-FasL and perforin/granzyme pathways may be 
involved in SJS/TEN. They found a direct correlation between disease severity and levels of 
perforin and granzyme B in patients with maculopapular exanthems, SJS and TEN. FasL 
was detected in the PBMCs and blister fluid of patients in SJS and TEN but not in those in 
maculopapular exanthema, suggesting that Fas-FasL is involved in more severe reactions 
(Posadas, Padial et al. 2002). Nassif et al, also showed a potential role for cytokines in the 
pathogenesis of SJS/TEN. He found elevated levels of IFN-, soluble TNF, IL-10, soluble 
FasL in the blister fluid of TEN patients. Although they disputed the central role of FasL, 
they hypothesised that drug specific CTLs secrete IFN-, which activates keratinocytes to 
produce TNF, a cytokine that upregulates MHC class I molecules. This increases exposure of 
keratinocytes to CTL resulting in perforin/granzyme-mediated apoptosis. IL-10 serves to 
downregulate the inflammatory reaction (Nassif, Bensussan et al. 2004).  
2.6 Risk factors for SJS/TEN 
2.6.1 Genetic susceptibility 
It was observed in the 1990s that the most commonly offending drugs vary among different 
ethnic populations. In Western countries, the most commonly implicated agents of SJS/TEN 
were NSAIDs and sulphonamides (Roujeau, Kelly et al. 1995). In contrast, carbamazepine 
was found to be the leading cause of SJS/TEN in Southeast Asian countries, including India, 
Malaysia, Singapore, Taiwan and Hong Kong (Hung, Chung et al. 2005a). Interestingly, 
carbamazepine in Western countries causes more cases of DIHS than SJS/TEN. Allopurinol 
is also a frequent case of SJS/TEN and DIHS but does not appear to have a racial bias 
(Hung, Chung et al. 2007).  
The most striking genetic association was detected in a cohort of Han Chinese in Taiwan, 
where the HLA-B*1502 allele was found in 100% of the 44 patients with carbamazepine-
induced SJS/TEN and only 3% of the carbamazepine-tolerant individuals; OR 2504 [126–
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49522] (Chung, Hung et al. 2004). These findings were replicated in an extended cohort of 
subjects of Chinese descent originating from separated geographic areas of China, Taiwan, 
and the United States (Hung, Chung et al. 2006). This association with carbamazepine-
induced SJS/TEN, however, was not found in individuals with European (Lonjou, Thomas 
et al. 2006) and Japanese ancestries (Kaniwa, Saito et al. 2008), respectively, and therefore the 
allele appears relevant in the context of ethnicity. In a recent study comprising 12 patients of 
Northern European ancestry with carbamazepine-induced SJS/TEN, 5 (42%) carried the 
HLA-A*3101 allele, as compared with 10 (4%) of the 257 control subjects; OR  25.93 [4.93-
116.18] (McCormack, Alfirevic et al. 2011). The results of this study are yet to be replicated 
in other cohorts of subjects with Northern European ancestry. In a Japanese study, The HLA-
A*3101 allele was found in 5/6 (83.3%) carbamazepine-induced SJS/TEN compared to 
47/376 (12.5%) carbamazepine-tolerant patients; OR 33.9 [3.9-295.6]. Larger patient sample 
sizes are required to confirm this association in the Japanese where the allele frequency is 
9% (Ozeki, Mushiroda et al. 2011). Interestingly the HLA-A*3101 allele was shown to be 
associated with maculopapular exanthem (OR 17.5 [4.6-66.5]) but not SJS/TEN in a Han 
Chinese population (Wen, Lai et al. 2008). 
A study comprising a Han Chinese cohort in Taiwan demonstrated the presence of the HLA-
B*5801 allele in all 51 patients with allopurinol-induced SCAR (21 with TEN, 30 with DIHS) 
compared with only 15% (20/135) in allopurinol-tolerant subjects; OR 580.3 [34.4-9780.9] 
(Hung, Chung et al. 2005b).  
The role of these HLA alleles in the pathogenesis of SCAR is unclear. Certain HLA alleles 
may bind to particular drugs more robustly than other alleles. Furthermore, the binding of 
the drug in SJS/TEN is MHC class I restricted, which is consistent with the prominent role 
of CD8 cells in the pathogenesis of the disease. If an allele has a functional effect that may 
play a role in the pathogenesis of disease, this association will be consistently observed 
across different populations. The differences observed between the Chinese and European 
studies may be partly explained by the fact that pharmacogenetic studies are likely to yield 
positive results when conducted in a population with a high frequency of such an allele. The 
risk of disease from a genetic polymorphism is influenced by its prevalence. The HLA-
B*1502 allele frequency is 4.8 to 12.8% in Southeast Asians compared to 0-0.1% observed in 
Northern Europeans (Fig. 5). Therefore, HLA-B*1502 is of low prevalence in Caucasians and 
hence, if it is a true susceptibility allele, a very large sample size is required in this 
population to detect a significant odds ratio of sufficient power. In contrast, the allele 
frequency of HLA-A*3101 is 2-5% in Northern Europeans and the sample size required to 
demonstrate an association in a sufficiently powered study is less than that for the HLA-
B*1502 allele. The HLA-B*5801 allele, in contrast to HLA-B*1502 is more evenly distributed 
among different racial groups (Fig. 6) and hence, associations, albeit weaker, have been 
demonstrated in other ethnic groups such as the Southern Japanese (Kaniwa, Saito et al. 
2008) and in whites (OR 80 [34-157]) (Lonjou, Borot et al. 2008). Another explanation is that 
HLA-B*1502, is a marker of a true disease contributing allele through strong linkage 
disequilibrium, which varies between populations. In other words, the same high-risk allele 
may have a different pattern of association with marker alleles and therefore HLA-B*1502 is 
in strong linkage disequilibrium in the Han Chinese population, but not in a European 
population. It is also plausible that SJS/TEN is a polygenic disorder, with many 
susceptibility and protective alleles in genes involved in the pathogenesis of the disease. 
Polymorphisms in the proapoptotic gene Fas-L, the toll-like receptor 3 gene, and in the IL-4 
receptor/IL-13 signalling pathway have all been recently described in a Japanese study 
(Ueta, Sotozono et al. 2008).  Such alleles may also vary in different populations.  
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Fig. 5. The high variation in the prevalence of HLA-B*1502 across geographical regions. 
 
 
Fig. 6. The low variation in the prevalence of HLA-B*5801 across geographical regions. 
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The FDA and Health Canada have issued warnings for carbamazepine stating that persons 
with ancestry in genetically at-risk populations should be screened for the presence of HLA-
B*1502 prior to initiating treatment. Genetic screening for HLA-B*1502 in a high risk 
population such as the Han Chinese has a 100% sensitivity and 97% specificity and its 
presence confers a 7.7% positive predictive value for carbamazepine-induced SJS/TEN 
whereas its absence has a 100% negative predictive value (Hung, Chung et al. 2005a).  
A recent study demonstrated the benefit of genetic screening; in a Taiwanese population, 
screening for the HLA-B*1502 allele resulted in no cases of SJS/TEN in 4501 patients who 
were negative for the allele (Chen, Lin et al. 2011). The authors concluded that this would 
have prevented 10 cases of SJS/TEN. Despite the FDA recommendations, screening is not 
routinely performed partly because of the lack of availability of cost effective and rapid 
methods of detection (Fernando and Broadfoot 2010). However, many laboratories have 
now developed high resolution genetic testing using a sequence-specific primer assay 
method for the detection of this allele from whole blood samples and buccal swabs.  
The assay can be performed within 3-4 hours. Such a strategy has been very successful in 
virtually abolishing the incidence of HLA-B*5701-associated abacavir hypersensitivity in 
HIV-infected patients (Rauch, Nolan et al. 2006). Multiplexed PCRs can be utilized to assess 
multiple alleles. 
It is important to note that the HLA-B*1502 allele does not predispose to carbamazepine-
induced DIHS, maculopapular eruptions or other adverse reactions and continued vigilance 
for the symptoms of SCAR needs to be maintained if treatment is commenced (Hung, 
Chung et al. 2006). Currently, there is no recommendation for genetic screening prior to the 
commencement of allopurinol therapy. Although such a strategy is plausible, studies are 
required to determine the benefits of screening for the HLA*5801 allele in at risk 
populations.  
2.6.2 Diseases 
The EuroSCAR study showed that HIV infection conferred the highest risk of SJS/TEN; 
multivariate relative risk (mvRR) 12 [2.4-59]. Other disease associations included collagen 
vascular disease mvRR 2.2 [0.9-5.0], recent malignancy mvRR 2.7 [1.3-5.7], recent 
radiotherapy mvRR 2.1 [0.5-9.0], or acute infection in the past 4 weeks [1.2-2.3] 
(Mockenhaupt, Viboud et al. 2008).  
2.6.3 Pharmacokinetics  
The EuroSCAR study revealed an increased risk of SJS/TEN at higher doses of 
allopurinol; adjusted odds ratio (OR) 36 [17-76] for doses ≥200 mg daily compared with an 
adjusted OR 3.0 [1.1-8.4] for doses <200 mg daily (Halevy, Ghislain et al. 2008). This study 
also revealed that the risk was mostly confined to short-term use (≤8 weeks, unadjusted 
OR 261 [36-∞]). Allopurinol is ideally commenced at a dose of 100 mg daily and increased 
by 100 mg increments until the desired serum uric acid level is attained. Previous reports 
have shown that allopurinol is often commenced at inappropriate doses (Stamp, Gow et 
al. 2000) and that higher doses are associated with an increased incidence of acute events 
(McInnes, Lawson et al. 1981). It is likely that the rapid accumulation of the chemically 
reactive metabolite oxypurinol when higher doses of allopurinol are commenced 
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increases the risk of SJS/TEN (Kumar, Edward et al. 1996). This drug accumulation 
hypothesis is further supported by the 4.7 fold increased incidence of allopurinol-induced 
SCAR in renal insufficiency (Vazquez-Mellado, Morales et al. 2001). The established 
indications for allopurinol are treatment of hyperuricemia associated with chronic gout, 
acute uric acid nephropathy, recurrent uric acid stone formation, enzyme disorders of 
purine metabolism, and in the management of tumour lysis. Allopurinol is not indicated 
in the majority of patients with asymptomatic hyperuricemia (Dincer, Dincer et al. 2002). 
However, allopurinol is inappropriately prescribed in up to 86% of cases (Khoo and Leow 
2000). A comparison of allopurinol exposure between the SCAR (1989-1993)  
and EuroSCAR (1997-2001) studies showed a 2-3 fold increase in exposure for both 
patients and control subjects, which may be attributed to the increased prescribing of the 
drug for the treatment of asymptomatic hyperuricemia. The authors of the EuroSCAR 
study postulate that up to 48 of the 56 cases of allopurinol-induced SJS/TEN could  
have been prevented if the treatment guidelines for prescribing allopurinol were 
followed. 
Lamotrigine when commenced at high doses can also overwhelm the detoxifying capacity 
resulting in an increased risk of SJS/TEN and DIHS (Schlienger, Shapiro et al. 1998). The 
incidence has reduced significantly as a result of the now conventional practice of gradually 
titrating the dose (Mockenhaupt, Messenheimer et al. 2005). Coadministration of certain 
drugs can predispose to SCAR by competition for the same enzyme-binding site. Reactions 
to lamotrigine are more common when given in combination with valproic acid as the 
addition of valproic acid inhibits the clearance of lamotrigine by competing for glucoronic 
acid conjugation (Yalcin and Karaduman 2000). The role of slow acetylation phenotypes of 
N-acetyltransferase was thought to confer susceptibility of sulphonamide-induced SJS/TEN 
in two small studies (Dietrich, Kawakubo et al. 1995; Wolkenstein, Carriere et al. 1995) but 
this needs confirmation in larger studies.   
2.7 Diagnosis 
2.7.1 Skin biopsy 
A presumptive diagnosis of SJS/TEN is made clinically and is confirmed with a skin biopsy 
(Figs. 7 & 8). Early lesions demonstrate scattered necrotic keratinocytes in the epidermal 
layers at the level of the stratum spinosum and the basal cell layer. Later, full thickness 
epidermal necrosis is evident, which eventuates in the formation of subepidermal bullae. 
The mononuclear predominantly T cell dermal infiltrate is generally sparse but dense 
infiltrates can also be present. Quinn et al, has shown an extensive infiltrate was associated 
with a 71% mortality rate, a moderate infiltrate with a 53% mortality, and a sparse infiltrate 
with a 27% mortality, respectively (Quinn, Brown et al. 2005). A fresh sample for direct 
immunofluoresence (DIF) reveals an absence of immunoglobulin and complement 
deposition. Cultures on blood, wounds and mucosal lesions should be performed to 
evaluate for superinfection. Serology may be performed for Mycoplasma pneumoniae if 
indicated.  
A recent pilot study showed that serum granulysin levels may be raised early in the course 
of disease but rapidly wanes with progression of disease (Abe, Yoshioka et al. 2009). Further 
studies are required to determine whether this assay will prove to be a useful early 
diagnostic test for SJS/TEN.  
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Fig. 7. Low power view of a skin biopsy from a patient with SJS demonstrates separation of 
the epidermis from the dermis at the level of the stratum spinosum and basal cell layer 
resulting in the formation of subepidermal bullae (Hematoxylin-eosin, original 
magnification x40). 
 
 
Fig. 8. High power view of a skin biopsy from a patient with SJS shows necrosis of 
keratinocytes, and vacuolar degeneration of the basal cell layer. A sparse lymphocytic 
infiltrate is present at the dermoepidermal junction and displays satellitosis or clustering 
around dying basal cells (Hematoxylin-eosin, original magnification x200). 
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2.7.2 Allergy testing 
Skin tests and oral challenges are contraindicated in SJS/TEN because of the risk of 
inducing a recurrence of disease. Patch testing has not been investigated extensively. The 
biggest cohort comprised 22 patients and showed a poor sensitivity of only 9% 
(Wolkenstein, Chosidow et al. 1996). Lymphocyte transformation tests (LTTs) assess the 
proliferation of the patient’s peripheral blood T cells cultured in the presence of a suspected 
drug for 6 days by measuring the incorporation of 3H-thymidine during DNA synthesis. The 
result is expressed as a stimulation index, which is the ratio of cell proliferation with antigen 
and without antigen. The sensitivity of LTTs in SJS/TEN is greatly improved if the test is 
performed within 1 week of the onset of disease but becomes negative by 6 weeks (Kano, 
Hirahara et al. 2007). This may be attributed to loss of regulatory T cell function in the acute 
phase, which is then restored upon recovery (Takahashi, Kano et al. 2009). Recently, a new 
cytotoxicity assay combining the measurement of expression of the degranulation marker, 
CD107a, using flow cytometry and the release of the serine protease, granzyme B by Elispot 
after incubating the patient’s peripheral blood mononuclear cells with the suspected drug 
for 3 days (Zawodniak, Lochmatter et al. 2010). The test has very good specificity with all of 
the 16 controls having a negative test and good sensitivity with 10 of the 12 patients having 
a positive result. One role of these in vitro tests is to determine the culprit drug when more 
than one drug is suspected.  
2.8 Differential diagnosis  
SJS/TEN is differentiated from other conditions on the basis of the acute onset of disease, 
the presence of targetoid and vesiculobullous lesions, sloughing of the epidermis, severe 
mucosal involvement, the histologic finding of full thickness epidermal necrosis, and a 
negative DIF. In EM major, erosive mucous membrane involvement is present but in 
contrast to SJS, the patient has typical target lesions mainly affecting the extremities and it is 
often induced by acute or recurrent HSV infection.  The clinical manifestations of drug-
induced maculopapular exanthems (MPE) are variable and often polymorphic and lesions 
may have a target-like appearance. Fever may be present but mucosal involvement is 
absent. The histopathology typically shows an interface dermatitis with hydropic 
degeneration of the basal cell layer. Some exanthems may progress to more severe reactions 
such as SJS/TEN or DIHS. Generalized bullous fixed drug eruption (GBFDE) features large 
brownish violaceous patches upon which flaccid blisters arise. These blisters affect only a 
small percentage of the TBSA. Mucosal involvement is rare and fever is absent. Most 
patients report a history of a similar local reaction or fixed drug eruption. 
Staphylococcal scalded skin syndrome (SSSS) usually affects children under the age of 5 years 
and patients present with fever, erythema and painful skin, followed by blistering, which is 
typically accentuated in areas of friction and around orifices. SSSS is caused by the systemic 
distribution of epidermolytic toxins produced by certain strains of Staphylococci. These toxins 
cause separation at the level of the stratum granulosum, the upper layer of the epidermis, 
resulting in very superficial detachment of the skin and blistering. Mucous membrane 
involvement is rare. The condition usually but not always follows local or systemic 
staphylococcal infection. Adults are less susceptible as improved renal function allows for 
better clearance of the toxins. However SSSS has been described in adults who are 
immunosuppressed or in renal failure. Toxic shock syndrome (TSS) is caused by elaboration of 
toxins produced by Staphylococcus aureus and Streptococcus pyogenes that act as superantigens, 
which bind to the variable regions of  chains of antigen receptors on subsets of T cells and 
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cross-link them to the MHC molecules of antigen-presenting cells. This results in activation of 
large numbers of T cells (5-30%) and the massive release of cytokines including IL-2, TNF, 
lymphotoxin and IL-1. TSS is characterised by fever, diffuse red macular rash, hypotension 
and involvement of ≥3 organs: renal failure, hepatitis, thrombocytopenia, encephalopathy, 
mucous membrane hyperemia, gastrointestinal involvement with vomiting and diarrhoea.  
 
Bullous disease Fever Mucositis Rash DIF Onset 
Other notable 
features 
SJS/TEN + + 
Erythroderma 
Targetoid lesions 
Vesicles, bullae 
Erosions, 
detachment 
- Acute 
Starts on trunk, 
proximal upper 
limbs and face and 
then spreads 
EM Major + + 
Acral 
Target lesions 
- Acute 
HSV-induced 
recurrences 
Drug-induced 
MPE 
+/- - 
Variable 
Pleomorphic 
- Acute 
May progress to SJS 
or DIHS 
GBFDE - - 
Brown patches 
Large bullae 
- Acute 
Antecedent local 
reaction 
Small % TBSA 
SSSS 
+ - 
Erythroderma 
Skin tenderness 
Periorificial crusting
- Acute 
Children under 5 
Adults with chronic 
renal failure and on 
immunosuppressive 
therapy 
TSS + + 
Diffuse red macular 
rash 
Desquamation of 
palms and soles 
- Acute 
Hypotension 
Multiple organ 
failure 
Drug-induced 
linear IgA 
dermatosis 
- - Tense bullae + Acute 
Vancomycin 
Pruritus 
PNP - + 
Polymorphous 
Bullae 
+ Gradual  
Drug-induced 
Pemphigus 
- - 
Erosions 
Crusts 
+ Gradual Thiol drugs 
Drug-triggered 
pemphigus 
- + 
Mucosal erosions 
Flaccid bullae 
+ Gradual Non-thiol drugs 
AGVHD + + 
Morbilliform rash 
Bullae 
Erosions, 
detachment 
- Acute 
Starts acrally and 
then spreads 
AGEP + +/- 
Small nonfollicular 
pustules 
Erythroderma 
- Acute  
SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis; EM, erythema multiforme;  
MPE, maculopapular exanthem; GBFDE, generalized bullous fixed drug eruption; SSSS, staphylococcal 
scalded skin syndrome; TSS, toxic shock syndrome; PNP, paraneoplastic pemphigus; AGVHD, acute 
graft versus host disease; AGEP, acute generalized exanthematous pustulosis 
Table 2. The differential diagnosis of SJS/TEN 
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Desquamation occurs after 1-2 weeks and predominantly affects the palms and soles. 
Approximately 50% of cases are menstrually related due to the prolonged application of 
absorbent tampons. Notably, 50% of cases of TSS are not associated with menstruation. Non-
menstrual cases of TSS usually complicate the use of barrier contraceptives, surgical and 
postpartum wound infections, burns, cutaneous lesions, osteomyelitis, and arthritis. Although 
most cases of TSS occur in women, about 25% of non-menstrual cases occur in men.  
Autoimmune bullous diseases such as drug-induced linear IgA bullous dermatosis, drug-
induced pemphigus, and paraneoplastic pemphigus need to be considered in the differential 
diagnosis of SJS/TEN. These conditions, in contrast to SJS/TEN, usually have a chronic 
course and are characterized by acantholysis on histopathology and immunoglobulin 
deposition on DIF. Bullous pemphigoid (BP) is a chronic disease that is typified by a tense 
bullous eruption that primarily affects individuals in the fifth through seventh decades of 
life.  
Acute graft versus host disease (AGVHD) shares many of the same clinical, pathologic and 
immunologic features as SJS/TEN. Both conditions are mediated by cytotoxic T cells, which 
results in epidermal necrosis and keratinolysis (Schulz and Sheridan 2006). Furthermore, 
bone marrow transplantation patients receive medications that can trigger SJS/TEN. 
AGVHD generally occurs 4 weeks after stem cell transplantation. Patients describe a 
sensation of skin pain and itching followed by a morbilliform rash that in severe cases 
becomes generalized with diffuse areas of epidermal necrosis. Mucositis is usually present. 
AGVHD frequently begins acrally and spreads proximally in contrast to TEN, which begins 
on the trunk and spreads distally. Also, the early exanthem of AGVHD has a folliculocentric 
distribution. 
AGEP is characterized by fever and as the disease progresses, widespread erosions 
mimicking SJS/TEN may be evident. Mucous membrane involvement is unusual and if 
present is mild. 
2.9 Treatment 
2.9.1 Supportive care 
Immediate discontinuation of the culprit drug is mandatory to reduce mortality. As the 
management of TEN is similar to that of extensive burns, a transfer to a burns unit reduces 
morbidity and mortality. The unit has expertise in providing analgesia, ensuring adequate 
enteral or parenteral nutrition, maintaining fluid and electrolyte balance, and managing 
wounds. Ophthalmologic consultation is important in SJS/TEN and the combination of 
aggressive lubrication, topical antibiotics, topical corticosteroids, and lysis of adhesions may 
attenuate the acute ocular manifestations.  However, these measures have only a modest 
effect on the long term ocular complications. Recently, the application of amniotic 
membranes has proved effective in preserving visual acuity and an intact ocular surface 
(Shammas, Lai et al. 2010). The benefit may be derived from creating a physical barrier 
between inflamed and denuded mucosal surfaces that minimizes the formation of 
adhesions. The membrane may also have antiinflammatory and antifibrotic effects. 
Other supportive measures include hygienic mouthwashes and topical oral anaesthetics, 
and monitoring for urinary retention. 
2.9.2 Corticosteroids 
The role of corticosteroids in the treatment of SJS/TEN is controversial. Corticosteroids 
given 48 hours or more prior to admission are associated with an increase incidence of 
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infection, length of hospital admission, and mortality in children and adults (Rasmussen 
1976; Ginsburg 1982; Engelhardt, Schurr et al. 1997). A study in 1986 of 30 patients with TEN 
with an average TBSA involvement > 80% were equally divided into those receiving 
supportive care alone and those receiving dexamethasone at varying doses (Halebian, 
Corder et al. 1986). Although the incidence of sepsis was not significant different between 
the groups, the survival following onset of sepsis was less in the corticosteroid treated 
group. The use of corticosteroids doubled the rate of mortality (66% versus 33%). 
Corticosteroids do not prevent SJS/TEN from occurring and have no effect on arresting 
disease progression (Samimi and Siegfried 2002).  A retrospective analysis of 379 patients 
from the EuroSCAR study found no benefit from corticosteroids or IVIg compared to 
supportive care alone (Schneck, Fagot et al. 2008).  
The poor outcomes may have resulted from inadequate doses and the delay in the initiation 
of corticosteroid therapy. In a prospective study of 16 children with SJS in 1997, 10 received 
methylprednisolone (4 mg/kg/daily) within 3 days of the onset of rash whilst 6 received 
supportive care only; corticosteroids were associated with decreased length of fever and 
duration of skin eruption (Kakourou, Klontza et al. 1997). The use of pulsed IV 
corticosteroids has also been shown in retrospective analyses to reduce mortality. The 
initiation of IV methylprednisolone 500-1000 mg/daily for 3-4 days may also prevent ocular 
complications of cicatrization and preservation of visual acuity (Araki, Sotozono et al. 2009). 
The benefits of early pulsed therapy with IV corticosteroids need to be further evaluated in 
randomised control trials.  
The current level of evidence suggests that high dose corticosteroids may be beneficial if 
commenced early in the course of disease with vigilant monitoring for emergence of 
infection. However, further evaluation in randomised control trials are required to confirm 
these benefits 
2.9.3 Intravenous immunoglobulin (IVIg) 
The rationale for the use of IVIg is based on its ability in vitro to block Fas and subsequently 
FasL-mediated apoptosis of keratinocytes. The beneficial role of IVIg in SJS/TEN has been 
demonstrated in retrospective studies. The largest such study to date comprised 48 patients 
with TEN recruited from centres across Europe and the United States. Treatment with IVIg 
resulted in a more rapid cessation of epidermal detachment and a survival rate of 88%. The 
authors subsequently recommended a dose of 1 g/kg/daily for 3 days (Prins, Vittorio et al. 
2003). Studies have also demonstrated benefit when investigators have compared the rates 
of mortality following the use of IVIg with the pre-treatment estimate using SCORTEN 
(Campione, Marulli et al. 2003; Metry, Jung et al. 2003; Yang, Xu et al. 2009).  
Despite the initial preponderance of evidence favouring the use of IVIg in SJS/TEN, a few 
published reports have not demonstrated any benefit. Most of these studies comparing the 
use of IVIg with supportive care alone used doses less than the recommended 2-3 g/kg. The 
largest restrospective analysis on the use of IVIg derived from the EuroSCAR study found 
no additional benefit from IVIg administered at a dose of 1.9 g/kg when compared to the 
use of supportive measures alone. This study involved the use of lower than recommended 
doses of IVIg and the patients from the IVIg group tended to have a greater TBSA 
involvement (Schneck, Fagot et al. 2008).  
Randomized control studies are required using sufficient doses of IVIg to characterize  
its benefit in not only reducing mortality but also arresting the rate of progression  
and hastening the rate of re-epithelialization. However, the evidence thus far, would 
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suggest that it should be at least considered as part of the adjunctive therapy in the 
treatment of SJS/TEN. 
2.9.4 Cyclosporine 
Cyclosporine inhibits CD8 activation and subsequent release of granulysin, granzyme and 
perforin as well as inhibiting the proapoptotic effect of NF-B. Several case and case series 
reports have shown arrest of disease progression and shorter time to re-epithelialization 
with doses varying from 3-10 mg/kg/daily for a period ranging from 8 days to several 
weeks. One study showed that outcomes for 10 patients treated with cyclosporine was 
superior to 6 patients treated with cyclophosphamide and corticosteroids with respect  
to re-epithelialization, disease progression and death (Arevalo, Lorente et al. 2000). 
However, randomised control studies are required to better define its benefits,  
the appropriate dose and duration of therapy. Furthermore, no studies have been 
published to date evaluating the efficacy of using both IVIg and cyclosporine but may be 
worthwhile considering as different pathways involved in the pathogenesis of SJS/TEN 
are targeted.  
2.9.5 Other pharmacotherapies 
Plasmapheresis and N-acetylcysteine-induced detoxification of drugs have demonstrated 
benefit in a small number of studies but larger randomized control studies are required to 
elucidate their role in the management of SJS/TEN. However, thalidomide, a potent 
inhibitor of TNF, was found in a double blinded randomised placebo controlled to be lethal 
in 10 of 12 patients as compared with 3 of 10 control subjects (Wolkenstein, Latarjet et al. 
1998). The exact mechanism underlying these fatalities is unknown but the drug is firmly 
contraindicated in SJS/TEN.  
2.9.6 Restricted use of related medications 
In addition to the restricted use of the same medication, structurally similar drugs should 
also be avoided. The aromatic anticonvulsants carbamazepine, phenytoin and phenobarbitol 
cross react with one another. Cross reactivity resulting in SJS/TEN can also occur across 
different classes of beta-lactam antibiotics, such as penicillins, cephalosporins and 
carbapenems.  Administration of a structurally related drug can also result in different 
reactions. One case report described a patient with ceftriaxone-induced TEN who developed 
immediate anaphylaxis following the administration of piperacillin/tazobactam (Lam, 
Randhawa et al. 2008). The risk of SJS/TEN with structurally distinct agents within the same 
class of drug is less clear. For example, the cross reactivity between a priopionic acid NSAID 
and an enolic acid NSAID is unknown. The safest practice is to restrict all NSAIDs following 
NSAID-induced SJS/TEN.  
3. Drug induced hypersensitivity syndrome 
3.1 Nosology 
The term hypersensitivity syndrome has been used for decades to describe a cutaneous drug 
reaction accompanied by involvement of internal organs. In 1938, Merritt and Putnam 
described a toxic reaction to phenytoin characterized by exfoliative dermatitis, fever and 
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eosinophilia (Merritt and Putnam 1938). This was distinguished from those patients who 
developed a mild, morbilliform rash. The anticonvulsant hypersensitivity syndrome was 
named in 1988 by Shear and Spielberg to refer the similar cutaneous and systemic 
manifestations of idiosyncratic reactions to a range of anticonvulsant medications including 
phenytoin, phenobarbitol and carbamazepine (Shear and Spielberg 1988). In 1996, Bocquet 
et al introduced the term drug reaction with eosinophilia and systemic symptoms (DRESS) 
to distinguish it from drug-induced pseudolymphoma and other drug reactions that are not 
associated with eosinophilia (Bocquet, Bagot et al. 1996). Finally, Shiohara et al proposed the 
term drug induced hypersensitivity syndrome (DIHS) to include patients who may not have 
marked eosinophilia but have other evidence of leukocyte abnormalities, internal organ 
involvement and evidence of HHV-6 reactivation (Suzuki, Inagi et al. 1998; Shiohara, Inaoka 
et al. 2006).  
3.2 Epidemiology 
The incidence of DIHS is estimated to be between 1 in 1000 and 1 in 10000 to phenytoin 
(Gennis, Vemuri et al. 1991). The true incidence remains to be determined because of the 
variable presentations and the lack of universally accepted criteria. The JSCAR and 
RegiSCAR studies will provide more accurate reporting on the basis of stringent criteria. 
Preliminary data from the RegiSCAR study suggests that it affects males and females 
equally with a mean age of 47.4 years (range 3-84 years) (Mockenhaupt 2007).  
3.3 Etiology and clinical features 
Various diagnostic criteria have been proposed. Bocquet et al stipulated the presence of  (1) 
cutaneous drug eruption; (2) hematologic abnormalities including eosinophilia greater than 
1.5 x109/L or the presence of atypical lymphocytes; and (3) systemic involvement including 
adenopathy greater than 2 cm in diameter, hepatitis (liver transaminase values >2 normal), 
interstitial nephritis, interstitial pneumonia, or carditis. 
Kardaun et al developed a scoring system to validate the diagnosis using fever 38.5C, 
lymphadenopathy, eosinophilia  700/L, atypical lymphocytosis, extensive skin rash 
(>50%), visceral organ involvement (liver, kidney, lung, heart, pancreas), prolonged 
resolution of the rash (15 days), and the absence of infectious diseases serology (hepatitis 
A, B and C, Epstein Barr virus, cytomegalovirus, mycoplasma and chlamydia), negative 
autoimmune serology (ANA) and negative blood cultures as supportive criteria (Kardaun, 
Sidoroff et al. 2007). 
The potential role of HHV-6 in the pathogenesis of DIHS was incorporated into the criteria 
for DIHS by the JSCAR group (Shiohara, Iijima et al. 2007): (1) maculopapular rash 
developing more than 3 weeks after starting a limited number of drugs; (2) prolonged 
clinical symptoms 2 weeks after discontinuation of the causative drug; (3) fever greater than 
38° C; (4) liver abnormalities (eg, ALT levels >100 U/L); (5) leukocyte abnormalities such as 
leukocytosis (>11 x 109/L), atypical lymphocytosis (>5%), and/or eosinophilia  
(>1.5 x 109/L); (6) lymphadenopathy; and (7) HHV-6 reactivation. Diagnosis of typical DIHS 
requires the presence of all 7 criteria. If criteria 1-5 are present only, then a diagnosis of 
atypical DIHS is made. 
The syndrome typically begins 3 weeks to 3 months after commencing therapy with a 
limited number of drugs of which the most prominent ones are listed below. 
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Carbamazepine 
Phenytoin 
Phenobarbitol 
Zonisamide 
Lamotrigine 
Allopurinol 
Dapsone 
Sulphasalazine 
Mexiletine 
Minocycline 
Strontium ranelate 
Abacavir 
Table 3. The main causative drugs of DIHS 
High-grade fever (38-40°C) is usually the first symptom followed by a pruritic 
maculopapular rash. Patients have facial oedema (Fig. 9), often with pinhead-sized pustules.  
The rash evolves, especially if the causative drug is not withdrawn into a severe exfoliative 
dermatitis (Fig. 10) or erythroderma with edematous, follicular and purpuric lesions. 
Cheilitis (Fig. 9), pharyngeal erythema and oral ulceration may occur but severe stomatitis is 
not present. Tender lymphadenopathy in more than two sites and bilateral swelling of 
salivary glands with xerostomia is evident early in the course of disease. 
Hepatosplenomegaly is a common finding. Leukocytosis with atypical lymphocytes and 
eosinophilia (60-70% of cases) is a prominent feature of this syndrome although the 
eosinophilia may not be observed for 1-2 weeks. Thrombocytopenia and anemia may also be 
present. Hypogammaglobulinema is noted at the onset of disease with the nadir occurring 
several days after the withdrawal of the causative drug (Kano, Inaoka et al. 2004). An 
overshoot in the IgG level occurs 1-2 weeks after the nadir before returning to normal on full 
recovery. Internal organ involvement is summarised in table 4. 
 
Manifestation Comments 
Hepatitis  
(mixed hepatocellular and cholestatic) 
71% 
 
Interstitial nephritis 11%, frequent with Allopurinol-induced DIHS 
Pneumonitis/pleuritis Common in minocycline and abacavir induced DIHS  
Myocarditis Occurs at onset or 40 days after onset of DIHS 
Limbic encephalitis 
2-4 weeks after onset of DIHS, HHV-6 reactivation in CSF 
May be assoiciated with SiADH 
CMV Gastrointestinal ulceration with 
bleeding 
4-5 weeks after onset of DIHS 
Haemaophagocytic syndrome Rare, occurs 2 weeks after onset of DIHS 
Parotid gland enlargement Rare 
Pancreatitis Rare 
Table 4. Internal organ involvement in DIHS 
The onset of symptoms is variable with patients developing 2-3 symptomatic features 
followed by stepwise development of other manifestations. In most cases, withdrawal of the 
drug is not followed by rapid resolution of symptoms. Many patients may continue to 
deteriorate and show periodic relapses for weeks after the withdrawal of the causative drug.  
www.intechopen.com
 Severe Cutaneous Adverse Reactions 
 
137 
 
Fig. 9. Facial erythema and edema with labial ulceration in a young woman with 
DIHS/DRESS.  
 
 
Fig. 10. Exfoliative dermatitis involving the hand in a young woman with DIHS/DRESS 
who had continued to ingest the culprit drug for 4 weeks when this image was taken. 
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Several reports have described the occurrence of autoantibody formation and autoimmune 
diseases up to 4 years after the acute resolution of DRESS (Aota and Shiohara 2009) and 
these include type 1 diabetes mellitus, autoimmune thyroid disease, scleroderma GVHD, 
SLE, and bullous pemphigoid. One of the likely explanations for the occurrence of 
autoimmune disease is the depletion of regulatory T cells upon recovery of disease.  
Abacavir, an HIV nucleoside analogue reverse transcriptase inhibitor causes a potentially life-
threatening hypersensitivity syndrome in approximately 5-8% of recipients within 6 weeks of 
therapy. The clinical and laboratory features of this syndrome differs from typical cases of 
DIHS/DRESS in that there is a predilection for the gastrointestinal system with nausea, 
abdominal pain, diarrhoea, and the respiratory tract with cough, pharyngitis and shortness of 
breath. Headache, myalgia and/or arthralgia may also be present. Eosinophilia is present in < 
10% of cases and liver function test abnormalities are detected in < 20% of cases (Peyriere, 
Dereure et al. 2006). Also, the manifestations resolve within 72 hours rather than having a 
protracted relapsing course and the role of herpetic viruses in this condition is unknown. 
3.4 Differential diagnosis 
Viral infections such as EBV, CMV, and measles can be distinguished by the absence of 
eosinophilia, hypogammaglobulinemia, and supportive serology. In children, DIHS is 
differentiated from Kawasaki’s disease by the absence of a bulbar conjunctivitis, strawberry 
tongue, coronary aneurysms, hypoalbuminemia and thrombocytosis. Serum sickness is 
characterized by urticarial lesions and the absence of internal organ involvement. Atopic 
erythroderma with bacterial infection does not usually involve hepatitis or nephritis. Drug-
induced pseudolymphoma from carbamazepine or phenytoin is distinguished from DIHS 
by the absence of internal organ involvement and the prompt resolution of symptoms when 
the drug is withdrawn. Cutaneous B and T cell lymphomas have an indolent course and 
characteristic histopathology. 
3.5 Pathology 
The histopathology of DIHS is relatively non-specific and consists of a lymphocytic infiltrate 
that is superficial, perivascular, dense and diffuse. Eosinophils may be present but is often 
absent. The presence of loose rather than discrete granulomatous aggregates of histiocytes 
have been recently reported (Figs. 11 & 12) (Fernando, Henderson et al. 2009). HHV-6 and 
DNA from other herpes viruses may be detected in skin lesions by PCR or in situ 
hybridization (Suzuki, Inagi et al. 1998).  
3.6 Drug allergy testing 
3.6.1 Patch tests 
Santiago et al recently studied the utility of patch testing in DIHS and found a positive 
reaction in 32% of the 56 patients. Patch testing was performed between 6 weeks and 6 
months after healing of the lesion and at least one month after corticosteroids were ceased. 
They found that 76% of the 17 patients with carbamazepine-induced DIHS were patch test 
positive but none of the 19 allopurinol-sensitive patients were positive to allopurinol and its 
metabolite, oxypurinol. No systemic reactions occurred during or after testing (Santiago, 
Goncalo et al. 2010). Hence patch testing may prove useful once the reagent and timing of 
such testing is optimized. Patch testing has, however, proven to be very useful in confirming 
suspected cases for abacavir hypersensitivity with a higher degree of specificity than can be 
confirmed clinically (Phillips, Wong et al. 2005).  
www.intechopen.com
 Severe Cutaneous Adverse Reactions 
 
139 
 
Fig. 11. Low power view of a skin biopsy from a patient with DIHS demonstrating the 
superficial dermal nature and perivascular distribution of the inflammatory infiltrate  
with acanthosis and hyperkeratosis of the epidermis (Hematoxylin-eosin, original 
magnification x40). 
 
 
Fig. 12. High power view of a skin biopsy from a patient with DIHS demonstrates 
granulomatous inflammation with prominent, but relatively loosely aggregated  
histiocytes, mixed with lymphocytes. Eosinophils are absent (Hematoxylin-eosin, original 
magnification x200). 
3.6.2 Lymphocyte transformation tests (LTTs) 
LTTs are usually negative up to 3 weeks after the onset of DIHS but most patients are 
positive at 5-7 weeks and have persistent responses even at 1 year. Treatment with 
corticosteroids did not affect the results (Kano, Hirahara et al. 2007). One possible 
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explanation for the negative LTT result during the acute phase of DIHS is the expansion T 
regulatory cells with a naïve phenotype (CD4CD25FoxP3), which then are depleted by 
apoptosis during the recovery phase. These regulatory T cells are capable of suppressing 
proliferation of memory T cells in LTTs (Takahashi, Kano et al. 2009).   
3.7 Pathogenesis 
The pathogenesis of DIHS is still to be fully elucidated. The precise role of HHV-6 in DIHS is 
unclear. The initiating event may be the reactivation of one or more herpetic viruses, which 
is clinically unapparent (Fig. 13). Virus-stimulated T cells may then cross react with drug-
derived hapten-protein conjugates that are presented by dendritic cells to naïve antigen-
specific CD4 T-cells with the subsequent differentiation into effector/memory CD4 cells. 
These dendritic cells may also activate CD8 T-cells by cross-presentation. The expansion of 
effector CD4 T-cells with their production of IFN- and other cytokines results in 
recruitment and activation of macrophages. Failure to eradicate the antigenic stimulus, in 
this instance due to the continued ingestion of the drug, causes persistent cytokine release 
and promotes differentiation of macrophages into epithelioid cells, which secrete large 
amounts of TNF promoting their fusion to form multinucleate giant cells (Fernando, 
Henderson et al. 2009). Analogous to that observed in GVHD, longitudinal real-time PCR 
analyses of viral loads in blood samples drawn from patients with DIHS show that various 
herpetic viruses are sequentially activated as a result of massive T cell stimulation, B cell loss 
and hypogammaglobulinemia (Hirahara, Kano et al. 2010); Activation of Epstein-Barr virus 
or HHV-6 extends to the sequential activation of HHV-7, cytomegalovirus and varicella-
zoster virus (Kano, Inaoka et al. 2004). The frequent deterioration or several exacerbations 
that occur despite continuation of the drug may at least be partly explained by sequential 
reactivation of herpetic viruses and the immune response to viral replication. An alternative 
explanation is that drug specific T cells are activated resulting in reactivation of the viral 
genome and sequential reactivation of herpes viruses (Fig. 14).  
Genetic susceptibility may also play a role as all patients with allopurinol-induced DIHS in a 
Han Chinese population harboured the HLA-B*5801 allele compared with 15% of control 
subjects (Hung, Chung et al. 2005b). Recently, an association was described between HLA-
A*3101 and DIHS in Northern Europeans; OR 12.41 [1.27-121.03] (McCormack, Alfirevic et 
al. 2011) and in the Japanese; OR 9.5 [4.6–19.5] (Ozeki, Mushiroda et al. 2011). In a Western 
Australian HIV Cohort Study, HLA-B*5701 was present in 14 (78%) of the 18 patients with 
abacavir hypersensitivity, and in four (2%) of the 167 abacavir tolerant patients; OR 117 [29-
481] (Mallal, Nolan et al. 2002). There is a discrepancy in the association of HLA-B*5701 and 
abacavir hypersensitivity across various racial groups The association was confirmed in a 
separate cohort of HIV-infected white Americans and was also found to confer susceptibility 
in Hispanics but not in blacks (Hughes, Mosteller et al. 2004). No association was found in a 
cohort of Korean patients (Park, Choe et al. 2009). The racial variation may be partly 
explained by the differences in MHC haplotypes across different racial groups. The 
Caucasian 57.1 ancestral haplotype, which confers susceptibility to abacavir hypersensitivity 
possibly as a result of strong linkage disequilibrium with other candidate genetic factors 
such as cellular chaperones (e.g. heat shock proteins), inflammatory cytokines (e.g. TNF), 
and proteins involved in the stress response (e.g. MHC class I chain-related genes, MIC-A 
and MIC-B). African populations do not demonstrate this haplotype (Cao, Hollenbach et al. 
2001). However, in a recent study by Saag et al, all 42 white patients with immunologically 
confirmed (i.e. positive patch tests) hypersensitivity to abacavir reactions were HLA-B*5701 
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positive (sensitivity 100%, OR 1945 [110-34,352]) but in addition all 5 black patients with 
immunologically confirmed hypersensitivity reactions were HLA-B*5701 positive 
(sensitivity 100%, OR 900 [ 38-21,045]. Screening for the HLA-B*5701 has eliminated 
immunologically confirmed cases of abacavir hypersensitivity (Mallal, Phillips et al. 2008). 
 
 
 
Fig. 13. One theory of the role of herpetic viruses in the pathogenesis of DIHS is the 
reactivation of HHV-6 within the T cell genome (A), which cross react with the culprit  
drug (B) resulting in the sequential activation of heterologous herpetic viruses (C).  
A
B 
C 
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Fig. 14. An alternative theory proposes that drug-specific T cells are activated (A) resulting 
in reactivation of HHV-6 from within the T cell genome (B) with subsequent sequential 
reactivation of heterologous herpetic viruses (C). 
A
B 
C 
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3.8 Treatment 
Early recognition of the syndrome with cessation of the causative drug is essential in 
improving patient outcomes. No randomized controlled trials have been conducted to 
determine the appropriate adjunctive therapy for DIHS. Oral corticosteroids at 1 
mg/kg/daily is commenced and tapered over at least 6-8 weeks to prevent relapse of 
various cutaneous and visceral manifestations of the syndrome. If symptoms deteriorate 
despite corticosteroid therapy then IVIg, plasma exchange (Higuchi, Agatsuma et al. 2005), 
rituximab or a combination of these modalities could be considered although the evidence 
for their use is currently scant. 
4. Acute generalized exanthematous pustulosis 
4.1 Nosology 
In 1980, Beylot et al introduced the term acute generalized exanthematous pustulosis 
(AGEP) to describe acute pustular reactions with distinct clinical and histological features 
thereby differentiating it from pustular psoriasis (Beylot, Bioulac et al. 1980).  
4.2 Demography 
AGEP is rare with an incidence of 1-5 cases per million per year (Sidoroff, Halevy et al. 
2001). The EuroSCAR study comprising 97 validated cases of AGEP recruited from Austria, 
France, Israel, Italy and the Netherlands, revealed a mean age (SD) of 56 (21) years and a 
female preponderance with a male/female ratio of 0.8 (Sidoroff, Dunant et al. 2007). The 
predominance in women was shown to be even greater in case series reports from Taiwan 
(68.7% of 16 cases) (Chang, Huang et al. 2008), and Israel (76.9% of 13 cases) (Davidovici, 
Dodiuk-Gad et al. 2008). AGEP has been reported in children, with the largest pediatric 
series of 20 cases from China (Zhang, Chen et al. 2008).   
4.3 Clinical features 
The clinical manifestations are characterized by fever and a pruritic or burning edematous 
erythema followed by the rapid appearance of dozens of small (< 5 mm) non-follicular 
sterile pustules (Fig. 15). The skin lesions are often accentuated in the intertriginous areas.   
 
 
Fig. 15. The lesions of AGEP occur rapidly and are characterized by dozens of small  
(< 5 mm) non-follicular sterile pustules. 
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There is usually an accompanying marked neutrophilia (7 x 109/L) and in a third of cases, a 
mild eosinophilia. A mild non-erosive mucous membrane involvement occurs in 20% of 
cases. Internal organ involvement is uncommon and usually is confined to a slight reduction 
in creatinine clearance and mild elevation of aminotransferases. The clinical course is 
characterized by spontaneous resolution of skin and systemic manifestations over a period 
of up to 15 days once the offending agent is withdrawn. AGEP has a favourable prognosis; 
the reported mortality rate is up to 5% and poor outcomes usually result from secondary 
infection in the elderly or those patients with significant comorbidities.  
4.4 Etiology 
AGEP is caused by drugs in at least 90% of cases. According to the EuroSCAR study, the 
agents conferring the highest risk are pristinamycin, aminopenicillins, hydroxychloroquine, 
antibacterial sulphonamides, terbinafine and diltiazem (Sidoroff, Dunant et al. 2007). The 
latent period is short (usually 1-5 days) with the EuroScar study demonstrating that it may 
vary for different drugs. For antibiotics, including sulphonamides, the median latent period 
was 1 day, and for other drugs it was 11 days (Sidoroff, Dunant et al. 2007).  
Contact sensitivity has been implicated in a few case reports. Causative agents include 
mercury, and bufexemac, a potent topical NSAID. Neither of these agents was implicated in 
the 97 cases of AGEP in the EuroScar study. The role of infectious agents in AGEP has been 
suggested in various case reports due to the absence of an inciting drug. The organisms 
include coxsackie B4, cytomegalovirus, parvovirus B19, Chlamydia pneumoniae, and 
Escherichia coli. No significant risk for infection was found in the EuroScar study although 
the study was not designed to identify potential causative organisms. Spider bites were 
suggested as a cause AGEP in a series of three cases from Israel, presumably as a result of 
the venom’s ability to induce IL-8 and GM-CSF (Davidovici, Pavel et al. 2006). Finally, as 
illustrated in two recent cases, AGEP may develop without preceding medication or disease 
(Birnie and Litlewood 2008).  
4.5 Pathogenesis 
The pathogenesis of AGEP has been elucidated by patch (Schaerli, Britschgi et al. 2004) and 
in vitro tests (Girardi, Duncan et al. 2005) and initially involves activation, expansion and 
subsequent migration of drug-specific CD4 and CD8 cells to the skin. The initial influx of 
CD8 cytotoxic T cells results in apoptosis of keratinocytes and the formation of subcorneal 
vesicles. The infiltrating CD4 cells release CXCL-8, which results in recruitment of 
neutrophils, and granulocyte macrophage-colony stimulating factor (GM-CSF), which 
prevents apoptosis of neutrophils. This results in the conversion of vesicles into pustules. 
CD4 cells also release IFN-, which stimulates keratinocytes to secrete CXCL-8, as well as 
RANTES and IL-5, which contributes to the eosinophilia observed in some patients 
(Britschgi, Steiner et al. 2001). Resident Langerhans’ cells may present drug antigens to CD4 
cells and keratinocytes may act as antigen presenting cells to CD8 cells thereby augmenting 
the neutrophil-mediated inflammatory response. Genetic susceptibility to AGEP has not 
been robustly examined and therefore remains largely unknown.  
4.6 Diagnostic tests 
A pustular smear should be performed to exclude an infectious aetiology. A full blood 
count will reveal a neutrophilia. A skin biopsy may show (spongiform or non-
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spongiform) subcorneal and/or intradermal pustules, edema of the papillary dermis, 
perivascular infiltrates with neutrophils and exocytosis of some eosinophils and focal 
necrotic keratinocytes (Fig. 16). The typical changes of psoriasis such as acanthosis and 
papillomatosis are usually absent. Patch testing may be useful in confirming the 
association between AGEP and the culprit drugs. In a controlled study, patch tests were 
positive in half of the 14 cases of AGEP (Wolkenstein, Chosidow et al. 1996). Readings 
should not be restricted to 24 and 48 hours after the application of the drug but should 
also be determined at 96 and 120 hours to maximise sensitivity. Pustule formation is often 
observed in positive patch tests in cases of AGEP. The test can be conducted one month 
after resolution of the disease. The risk of AGEP with patch testing is considered to be low 
but not negligible (Mashiah and Brenner 2003). A small number of studies have supported 
a role for LTT, IFN- release, lymphokine macrophage migration inhibition factor release 
assays but these in vitro tests are not widely available and its value remains to be 
determined in large cohorts.  
 
 
Fig. 16. A moderate power view of a skin biopsy from a patient with AGEP shows 
spongiform subcorneal pustules, edema of the papillary dermis and perivascular  
infiltrates with neutrophils and exocytosis of some eosinophils. 
4.7 Differential diagnosis 
AGEP, which is characterized by non-follicular pustules can be readily distinguished from 
diseases with follicular pustulosis such as bacterial folliculitis, furunculosis, acneiform 
eruptions, pustular contact dermatitis, dermatophyte infection, viral exanthema with 
primary vesiculation and secondary postulation, impetigo, Sweet syndrome and SSSS. Other 
diseases are not as easily differentiated from AGEP. Generalized pustular psoriasis 
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(Zumbusch psoriasis) is characterized by pustules that slowly develop on areas of psoriasis 
accompanied by the histological changes of psoriasis on skin biopsy. There is also usually a 
family history of psoriasis. Sneddon-Wilkinson disease (subcorneal pustulosis) and 
subcorneal IgA dermatosis are characterized by the subacute development of larger 
pustules than those that erupt in AGEP and maybe associated with hyopyon formation.  
A diagnostic score was devised to validate the diagnosis of AGEP based on the morphology, 
course of disease, and histology, and assist in the differentiation from similar diseases 
(Sidoroff, Halevy et al. 2001). 
4.8 Treatment 
As AGEP is a self-limiting disease with a favourable prognosis. Cessation of the causative 
agent and supportive treatment is usually all that his required. In the pustular phase, 
supportive measures consist of moist dressings with drying and disinfecting solutions to 
avoid superinfection. In the postpustular desquamation phase, emollients are used to 
optimise preservation of skin barrier function. In a study of nine cases from Israel, all of who 
made a full recovery, seven received supportive care alone and the other two received 
corticosteroids (Tamir, Wohl et al. 2006). It remains to be established whether oral or 
parenteral corticosteroids hasten the resolution of disease. A brief course of systemic 
corticosteroids may be considered in patients with severe and widespread inflammation of 
the skin. 
5. Conclusion 
SCARs such as SJS/TEN, DIHS/DRESS, and AGEP are idiosyncratic and specific types of 
reactions that have distinct clinical, laboratory and histological features. The definition of 
DIHS/DRESS has not been universally adopted and will need to be clarified once the role 
of herpetic viruses and characteristic histological features are known. The early 
identification of these reactions and the subsequent prompt withdrawal of therapy and 
the implementation of supportive and adjunctive therapies are crucial in minimising 
morbidity and rates of mortality. Multicentre randomized studies are required to adopt 
the most suitable therapies for these potentially life-threatening conditions. The 
emergence in the understanding of HLA susceptibility genes will enable patients to be 
screened for the risk of developing a SCAR and will hopefully be more widely performed 
once cost effective and rapid methods of detection are widely available to the prescribing 
doctor. 
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